Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | FDPS | P14324 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KDM5A | P29375 | 1/20 | 0.40 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17337686 | 0.98 | EGLN3 (0.48) | EGLN3THRBLMNAPOLBFDPS | |
| SCHEMBL3489062 | 0.88 | TBXAS1 (0.42) | EGLN3THRBLMNAPOLBFDPS | |
| SCHEMBL5521617 | 0.86 | TBXAS1 (0.49) | THRBLMNAFDPSHTTTSHR | |
| SCHEMBL5514714 | 0.85 | TBXAS1 (0.51) | LMNAKMT2AESR1TSHR | |
| SCHEMBL9845261 | 0.85 | TBXAS1 (0.51) | LMNAKMT2AESR1TSHR | |
| SCHEMBL9845290 | 0.85 | TBXAS1 (0.51) | LMNAKMT2AESR1TSHR | |
| Water SCHEMBL9845268 | 0.83 | TBXAS1 (0.50) | LMNAKMT2AESR1TSHR | |
| SCHEMBL24930971 | 0.82 | THRB (0.44) | THRBLMNAPOLBFDPSKMT2A | |
| SCHEMBL412090 | 0.82 | THRB (0.48) | THRBLMNAPOLBFDPSKMT2A | |
| SCHEMBL1178459 | 0.82 | LMNA (0.45) | THRBLMNAPOLBFDPSKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025202864-A1 | ENT1 INHIBITORS IN COMBINATION WITH ONCOLYTIC VIRUSES AND THEIR USE IN THE TREATMENT OF CANCER | iTeos Belgium SA (BE) | 2025-10-02 | — | — | WO | claimed |
| WO-2025126110-A1 | ENT1 INHIBITORS IN COMBINATION WITH BISPECIFIC ANTIBODIES | iTeos Belgium SA (BE) | 2025-06-19 | — | — | WO | claimed |
| WO-2025104613-A1 | ENT1 INHIBITORS IN COMBINATION WITH CHECKPOINT INHIBITORS | iTeos Belgium SA (BE) | 2025-05-22 | — | — | WO | claimed |
| CN-118591200-A | Surface modification layer, trans-perovskite battery and preparation method of trans-perovskite battery | 四川恒立聚能光电科技有限公司 | 2024-09-03 | — | — | CN | claimed |
| EP-3661921-B1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NODTHERA LTD (GB) | 2023-10-18 | — | — | EP | claimed |
| CN-116535365-A | Macrocyclic diamine derivatives and their combination with adenosine receptor antagonists as ENT inhibitors for the treatment of cancer | ITEOS比利时公司 | 2023-08-04 | — | — | CN | claimed |
| US-20230203058-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-06-29 | — | — | US | claimed |
| EP-4132933-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-02-15 | — | — | EP | claimed |
| EP-4029868-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4143179-B1 | AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-10-22 | — | — | EP | disclosed |
| EP-4635939-A1 | NOVEL LIPID COMPOUND AND LIPID NANOPARTICLE COMPOSITION COMPRISING SAME | Korea Institute of Science and Technology (KR) | 2025-10-22 | — | — | EP | disclosed |
| WO-2025202864-A1 | ENT1 INHIBITORS IN COMBINATION WITH ONCOLYTIC VIRUSES AND THEIR USE IN THE TREATMENT OF CANCER | iTeos Belgium SA (BE) | 2025-10-02 | — | — | WO | disclosed |
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| US-6162927-A | Endothelin antagonists | ABBOTT LABORATORIES (US) | 2000-12-19 | — | — | US | disclosed |
| US-5972064-A | USEFUL FOR FERTILIZER COMPOSITIONS | BASF AKTIENGESELLSCHAFT (DE) | 1999-10-26 | — | — | US | disclosed |
| CN-1219172-A | Novel benzo-1, 3-dioxolyl-and benzofuranyl-substituted pyrrolidine derivatives as endothelin antagonists | ABBOTT LAB CO (US) | 1999-06-09 | — | — | CN | disclosed |
| EP-0808297-B1 | USE OF NOT EASILY VOLATILISED PYRAZOL DERIVATIVES WITH HYDROPHILIC GROUPS AS NITRIFICATION INHIBITORS | BASF AG (DE) | 1999-05-12 | — | — | EP | disclosed |
| EP-0808297-A1 | USE OF NOT EASILY VOLATILISED PYRAZOL DERIVATIVES WITH HYDROPHILIC GROUPS AS NITRIFICATION INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 1997-11-26 | — | — | EP | disclosed |
| WO-1996024566-A1 | USE OF NOT EASILY VOLATILISED PYRAZOL DERIVATIVES WITH HYDROPHILIC GROUPS AS NITRIFICATION INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 1996-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | STAT6, NCOR2, NCOR1 | EGLN3 1288/4885THRB 84/4885LMNA 4019/4885 |
| US-20230203058-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | ENTPD1, SLC29A1, ENTPD5 | EGLN3 1568/4885THRB 2281/4885LMNA 3959/4885 |
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | STAT6, STAT5B, STAT5A | EGLN3 1034/4885THRB 333/4885LMNA 4150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.